Analysts Set Evommune, Inc. (NYSE:EVMN) Price Target at $38.60

Evommune, Inc. (NYSE:EVMN) has been given an average rating of “Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $39.1667.

Several research firms recently commented on EVMN. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. William Blair started coverage on shares of Evommune in a research report on Monday, December 1st. They set an “outperform” rating for the company. Cantor Fitzgerald started coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “overweight” rating for the company. Raymond James Financial assumed coverage on Evommune in a research note on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price target on the stock. Finally, Leerink Partners upgraded Evommune to a “strong-buy” rating in a research report on Monday, December 1st.

Hedge Funds Weigh In On Evommune

A hedge fund recently bought a new stake in Evommune stock. Capricorn Fund Managers Ltd purchased a new stake in Evommune, Inc. (NYSE:EVMN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 60,000 shares of the company’s stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned approximately 0.19% of Evommune at the end of the most recent reporting period.

Evommune Stock Up 3.3%

NYSE EVMN opened at $19.50 on Tuesday. The business’s 50-day simple moving average is $18.54. Evommune has a twelve month low of $13.89 and a twelve month high of $24.03. The firm has a market cap of $614.72 million and a PE ratio of -2.42.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.